RFK Jr. Announces Major Drug Price Reform Agreements with Pharma Giants

Health and Human Services Secretary Robert F. Kennedy Jr. announced agreements with 60 to 70 pharmaceutical companies to eliminate international price disparities. The administration is moving forward with the 'Most Favored Nation' policy to ensure U.S. drug prices align with the lower rates paid by other nations. Historically, Americans have paid between two to four times more for prescription medications compared to other developed countries. This aggressive reform aims to dismantle what the administration describes as an inefficient healthcare system that prioritized corporate profits over consumers. Market analysts expect these price caps to significantly impact the revenue streams and profit margins of major drugmakers like Pfizer and Eli Lilly. Consequently, the outlook remains bearish for healthcare giants and sector-specific ETFs such as XLV.